An antisense oligonucleotide targeted to a nucleic acid molecule encoding human apolipoprotein B, wherein said oligonucleotide is 100% complementary to said nucleic acid molecule and is a single-stranded chimeric oligonucleotide 20 nucleotides in length composed of a central gap region consisting of ten 2'-deoxynucleotides flanked on both sides by five-nucleotide wings composed of 2'-methoxyethyl (2'-MOE) nucleotides, and wherein the internucleoside linkages are phosphorothioate (P=S) throughout the oligonucleotide, and wherein all cytidine residues are 5-methylcytidines, and wherein said oligonucleotide specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding human apolipoprotein B, for use in: (a) treating an animal having a disease or condition associated with apolipoprotein B which involves abnormal lipid metabolism; (b) treating an animal having a disease or condition associated with apolipoprotein B which involves abnormal cholesterol metabolism; (c) treating an animal having a condition associated with apolipoprotein B, wherein the condition is atherosclerosis; (d) treating an animal having a condition associated with apolipoprotein B, wherein the condition is hyperlipidemia; (e) treating an animal having a disease associated with apolipoprotein B, wherein the disease is diabetes; (f) treating an animal having a condition associated with apolipoprotein B, wherein the condition is obesity; (g) treating an animal having a disease associated with apolipoprotein B, wherein the disease is cardiovascular disease; (h) therapy or prophylaxis, wherein said use comprises modulating glucose levels in an animal; (i) therapy or prophylaxis, wherein said use comprises modulating serum cholesterol levels in an animal; (j) therapy or prophylaxis, wherein said use comprises modulating lipoprotein levels in an animal; or (k) therapy or prophylaxis, wherein said use comprises modulating serum triglyceride levels in an animal. (a) treating an animal having a disease or condition associated with apolipoprotein B which involves abnormal lipid metabolism; (b) treating an animal having a disease or condition associated with apolipoprotein B which involves abnormal cholesterol metabolism; (c) treating an animal having a condition associated with apolipoprotein B, wherein the condition is atherosclerosis; (d) treating an animal having a condition associated with apolipoprotein B, wherein the condition is hyperlipidemia; (e) treating an animal having a disease associated with apolipoprotein B, wherein the disease is diabetes; (f) treating an animal having a condition associated with apolipoprotein B, wherein the condition is obesity; (g) treating an animal having a disease associated with apolipoprotein B, wherein the disease is cardiovascular disease; (h) therapy or prophylaxis, wherein said use comprises modulating glucose levels in an animal; (i) therapy or prophylaxis, wherein said use comprises modulating serum cholesterol levels in an animal; (j) therapy or prophylaxis, wherein said use comprises modulating lipoprotein levels in an animal; or (k) therapy or prophylaxis, wherein said use comprises modulating serum triglyceride levels in an animal.